$CDXC
ChromaDex Corp. Stock $cdxc

$cdxc Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000162828021021447 Filed on November 03, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q4
Revenue	$17.76M	$17.31M	$15.45M
YoY Change	14.94%	22.06%	18.03%
Cost Of Revenue	$6.891M	$6.730M	$6.020M
YoY Change	14.47%	17.53%	7.12%
Gross Profit	$10.87M	$10.58M	$9.420M
YoY Change	15.37%	25.12%	26.1%
Gross Profit Margin	61.2%	61.12%	60.97%
Selling, General & Admin	$15.14M	$18.42M	$14.51M
YoY Change	4.33%	56.01%	-4.48%
% of Gross Profit	139.3%	174.16%	154.03%
Research & Development	$1.045M	$996.0K	$990.0K
YoY Change	5.56%	18.43%	-13.16%
% of Gross Profit	9.62%	9.42%	10.51%
Depreciation & Amortization	$262.0K	$285.0K	$280.0K
YoY Change	-6.43%	1.79%	3.7%
% of Gross Profit	2.41%	2.69%	2.97%
Operating Expenses	$16.18M	$19.42M	$15.51M
YoY Change	4.35%	53.51%	-5.02%
Operating Profit	-$5.316M	-$8.841M	-$6.090M
YoY Change	-12.71%	110.7%	-31.26%
Interest Expense	-$9.000K	$15.00K	-$20.00K
YoY Change	-55.0%	-21.05%	-300.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$5.325M	-$8.856M	-$6.100M
YoY Change	-12.7%	109.86%	-31.07%
Income Tax
% Of Pretax Income
Net Earnings	-$5.325M	-$8.856M	-$6.100M
YoY Change	-12.7%	110.11%	-31.07%
Net Earnings / Revenue	-29.98%	-51.17%	-39.48%
Basic Earnings Per Share		-$0.13
Diluted Earnings Per Share	-$77.96K	-$0.13	-$98.58K
COMMON SHARES
Basic Shares Outstanding	68.29M shares	68.24M shares	61.79M shares
Diluted Shares Outstanding		68.24M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$28.22M	$33.10M	$16.70M
YoY Change	68.98%	113.84%	-11.22%
Cash & Equivalents	$28.22M	$33.10M	$16.70M
Short-Term Investments
Other Short-Term Assets	$1.859M	$1.762M	$1.150M
YoY Change	61.65%	74.46%	15.0%
Inventory	$13.60M	$12.68M	$11.68M
Prepaid Expenses
Receivables	$5.226M	$5.295M	$2.694M
Other Receivables	$2.100M	$2.300M	$900.0K
Total Short-Term Assets	$48.91M	$52.84M	$32.22M
YoY Change	51.79%	71.94%	-3.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.355M	$3.084M	$3.206M
YoY Change	129.41%	-6.74%	-14.85%
Goodwill
YoY Change
Intangibles	$857.0K	$908.0K	$1.082M
YoY Change	-20.79%	-20.84%	-17.47%
Long-Term Investments
YoY Change
Other Assets	$723.0K	$576.0K	$625.0K
YoY Change	15.68%	-36.7%	-17.98%
Total Long-Term Assets	$8.935M	$7.617M	$6.139M
YoY Change	45.54%	13.91%	-8.77%
TOTAL ASSETS
Total Short-Term Assets	$48.91M	$52.84M	$32.22M
Total Long-Term Assets	$8.935M	$7.617M	$6.139M
Total Assets	$57.84M	$60.45M	$38.36M
YoY Change	50.79%	61.57%	-4.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.42M	$10.80M	$9.445M
YoY Change	10.35%	57.01%	-1.88%
Accrued Expenses	$6.481M	$6.331M	$6.133M
YoY Change	5.67%	22.39%	38.91%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$20.00K	$13.00K	$30.00K
YoY Change	-33.33%	-83.75%	-88.46%
Total Short-Term Liabilities	$17.61M	$17.77M	$16.48M
YoY Change	6.9%	36.53%	9.38%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$11.00K	$20.00K
YoY Change	-100.0%	-45.0%	0.0%
Other Long-Term Liabilities	$8.500M	$7.222M	$5.440M
YoY Change	56.25%	47.69%	15.25%
Total Long-Term Liabilities	$8.500M	$7.233M	$5.460M
YoY Change	55.68%	47.31%	15.19%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.61M	$17.77M	$16.48M
Total Long-Term Liabilities	$8.500M	$7.233M	$5.460M
Total Liabilities	$26.11M	$25.00M	$21.93M
YoY Change	19.05%	39.46%	10.77%
SHAREHOLDERS EQUITY
Retained Earnings	-$169.0M	-$163.6M	-$141.8M
YoY Change	19.13%	20.56%	16.35%
Common Stock	$68.00K	$68.00K	$62.00K
YoY Change	9.68%	9.68%	3.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$31.73M	$35.45M	$16.42M
YoY Change
Total Liabilities & Shareholders Equity	$57.84M	$60.45M	$38.36M
YoY Change	50.79%	61.57%	-4.69%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q4
OPERATING ACTIVITIES
Net Income	-$5.325M	-$8.856M	-$6.100M
YoY Change	-12.7%	110.11%	-31.07%
Depreciation, Depletion And Amortization	$262.0K	$285.0K	$280.0K
YoY Change	-6.43%	1.79%	3.7%
Cash From Operating Activities	-$4.944M	-$5.919M	$20.00K
YoY Change	-24820.0%	54.14%	-103.28%
INVESTING ACTIVITIES
Capital Expenditures	-$2.000K	-$96.00K	$30.00K
YoY Change	-106.67%	60.0%	-110.71%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$2.000K	-$96.00K	$10.00K
YoY Change	-120.0%	60.0%	-96.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	63.00K	339.0K	1.180M
YoY Change	-94.66%	-30.82%	337.04%
NET CHANGE
Cash From Operating Activities	-4.944M	-5.919M	20.00K
Cash From Investing Activities	-2.000K	-96.00K	10.00K
Cash From Financing Activities	63.00K	339.0K	1.180M
Net Change In Cash	-4.883M	-5.676M	1.210M
YoY Change	-503.55%	66.45%	-1828.57%
FREE CASH FLOW
Cash From Operating Activities	-$4.944M	-$5.919M	$20.00K
Capital Expenditures	-$2.000K	-$96.00K	$30.00K
Free Cash Flow	-$4.942M	-$5.823M	-$10.00K
YoY Change	49320.0%	54.05%	-96.97%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90024
	dei	Entity Central Index Key EntityCentralIndexKey	0001386570
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Entity File Number EntityFileNumber	001-37752
	dei	Entity Registrant Name EntityRegistrantName	CHROMADEX CORPORATION
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-2940963
	dei	Entity Address Address Line1 EntityAddressAddressLine1	10900 Wilshire Blvd
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 600
	dei	Entity Address City Or Town EntityAddressCityOrTown	Los Angeles
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	City Area Code CityAreaCode	310
	dei	Local Phone Number LocalPhoneNumber	388-6706
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
	dei	Trading Symbol TradingSymbol	CDXC
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	68291456	shares
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	200000	USD
CY2021Q3	us-gaap	Restricted Cash RestrictedCash	200000	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33102000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16697000	USD
CY2021Q3	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	37000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	189000	USD
CY2021Q3	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	2300000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3049000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1226000	USD
CY2020Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	900000	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5295000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2694000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	12676000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	11683000	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	1762000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	1145000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	52835000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	32219000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3084000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3206000	USD
CY2021Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	908000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1082000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	576000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	625000	USD
CY2021Q3	us-gaap	Assets Assets	60452000	USD
CY2020Q4	us-gaap	Assets Assets	38358000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	10804000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9445000	USD
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6331000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6133000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	447000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	589000	USD
CY2021Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	13000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	31000	USD
CY2021Q3	us-gaap	Deferred Income Current DeferredIncomeCurrent	175000	USD
CY2020Q4	us-gaap	Deferred Income Current DeferredIncomeCurrent	278000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	17770000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16476000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	4346000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	4441000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2876000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	997000	USD
CY2021Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	11000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	20000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	25003000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	21934000	USD
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68094000	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	68094000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	61881000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61881000	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	68000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	62000	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	199011000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	158190000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-163628000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-141825000	USD
CY2021Q3	us-gaap	Translation Adjustment Functional To Reporting Currency Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax	-2000	USD
CY2020Q4	us-gaap	Translation Adjustment Functional To Reporting Currency Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax	-3000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	35449000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	16424000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	60452000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	38358000	USD
CY2021Q3	us-gaap	Revenues Revenues	17308000	USD
CY2020Q3	us-gaap	Revenues Revenues	14180000	USD
	us-gaap	Revenues Revenues	49690000	USD
	us-gaap	Revenues Revenues	43812000	USD
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	6730000	USD
CY2020Q3	us-gaap	Cost Of Revenue CostOfRevenue	5726000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	19068000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	17959000	USD
CY2021Q3	us-gaap	Gross Profit GrossProfit	10578000	USD
CY2020Q3	us-gaap	Gross Profit GrossProfit	8454000	USD
	us-gaap	Gross Profit GrossProfit	30622000	USD
	us-gaap	Gross Profit GrossProfit	25853000	USD
CY2021Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	7221000	USD
CY2020Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5223000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	19711000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	14629000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	996000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	841000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2787000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2545000	USD
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11202000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6586000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	29881000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22452000	USD
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	19419000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	12650000	USD
	us-gaap	Operating Expenses OperatingExpenses	52379000	USD
	us-gaap	Operating Expenses OperatingExpenses	39626000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8841000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4196000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21757000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13773000	USD
CY2021Q3	us-gaap	Interest Expense InterestExpense	15000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	19000	USD
	us-gaap	Interest Expense InterestExpense	46000	USD
	us-gaap	Interest Expense InterestExpense	55000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-8856000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-4215000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-21803000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-13828000	USD
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	68236000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	68236000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61695000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61695000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	66811000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	66811000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60797000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60797000	shares
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	42142000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	341000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1822000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-8856000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	35449000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	16424000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	400000	USD
	cdcx	Issuance Of Common Stock Net Of Offering Costs Amount IssuanceOfCommonStockNetOfOfferingCostsAmount	26740000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9365000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4722000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-21803000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	35449000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	21581000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	547000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1574000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-4215000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	19487000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	20445000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	100000	USD
	cdcx	Issuance Of Common Stock Net Of Offering Costs Amount IssuanceOfCommonStockNetOfOfferingCostsAmount	4856000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2859000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5158000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-3000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-13828000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	19487000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-21803000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-13828000	USD
	us-gaap	Depreciation Depreciation	679000	USD
	us-gaap	Depreciation Depreciation	652000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	174000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	182000	USD
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	385000	USD
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	284000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4722000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5158000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-152000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-2737000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-87000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-75000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	2448000	USD
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-1698000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	992000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-504000	USD
	cdcx	Implementation Costs For Cloud Computing Arrangement ImplementationCostsForCloudComputingArrangement	150000	USD
	cdcx	Implementation Costs For Cloud Computing Arrangement ImplementationCostsForCloudComputingArrangement	0	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	608000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	185000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1359000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2745000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	198000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	757000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-95000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-53000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-103000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	56000	USD
	cdcx	Increase Decrease In Principal Payments On Operating Leases IncreaseDecreaseInPrincipalPaymentsOnOperatingLeases	472000	USD
	cdcx	Increase Decrease In Principal Payments On Operating Leases IncreaseDecreaseInPrincipalPaymentsOnOperatingLeases	440000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19219000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10622000	USD
	cdcx	Purchases Of Leasehold Improvements And Equipment PurchasesOfLeaseholdImprovementsAndEquipment	-407000	USD
	cdcx	Purchases Of Leasehold Improvements And Equipment PurchasesOfLeaseholdImprovementsAndEquipment	-147000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	18000	USD
	cdcx	Investment In Other Long Term Assets InvestmentInOtherLongTermAssets	0	USD
	cdcx	Investment In Other Long Term Assets InvestmentInOtherLongTermAssets	16000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-407000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-181000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	26740000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4856000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9365000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2859000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	47000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	30000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	27000	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	216000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	36031000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7469000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	16405000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3334000	USD
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	200000	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	200000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16697000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18812000	USD
CY2021Q3	us-gaap	Restricted Cash RestrictedCash	200000	USD
CY2020Q3	us-gaap	Restricted Cash RestrictedCash	200000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33102000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15478000	USD
	us-gaap	Interest Paid Net InterestPaidNet	1000	USD
	us-gaap	Interest Paid Net InterestPaidNet	11000	USD
	cdcx	Right Of Use Assets And Operating Lease Liabilities Incurred Due To Lease Amendment RightOfUseAssetsAndOperatingLeaseLiabilitiesIncurredDueToLeaseAmendment	2209000	USD
	cdcx	Right Of Use Assets And Operating Lease Liabilities Incurred Due To Lease Amendment RightOfUseAssetsAndOperatingLeaseLiabilitiesIncurredDueToLeaseAmendment	716000	USD
	cdcx	Financing Lease Obligation Incurred For Purchase Of Computer Equipment And Software FinancingLeaseObligationIncurredForPurchaseOfComputerEquipmentAndSoftware	0	USD
	cdcx	Financing Lease Obligation Incurred For Purchase Of Computer Equipment And Software FinancingLeaseObligationIncurredForPurchaseOfComputerEquipmentAndSoftware	47000	USD
	us-gaap	Nature Of Operations NatureOfOperations	Nature of BusinessChromaDex is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient NIAGEN®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent and/or licensed rights portfolio. ChromaDex delivers NIAGEN® as the sole active ingredient in its consumer product TRU NIAGEN®. The Company also has an analytical reference standards and services segment, which focuses on natural product fine chemicals, known as phytochemicals, and related chemistry services.
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19200000	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33100000	USD
CY2021Q3	us-gaap	Restricted Cash RestrictedCash	200000	USD
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	Reclassifications: Certain prior period results have been reclassified to be consistent with the current period presentation.
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-8856000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-4215000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-21803000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-13828000	USD
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	68236000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	68236000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61695000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61695000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	66811000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	66811000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60797000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60797000	shares
	cdcx	Nonvested Shares Of Restricted Stock NonvestedSharesOfRestrictedStock	200000	shares
CY2021Q3	cdcx	Nonvested Shares Of Restricted Stock NonvestedSharesOfRestrictedStock	200000	shares
	cdcx	Nonvested Shares Of Restricted Stock NonvestedSharesOfRestrictedStock	200000	shares
CY2020Q3	cdcx	Nonvested Shares Of Restricted Stock NonvestedSharesOfRestrictedStock	200000	shares
CY2021Q3	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	2600000	USD
CY2020Q3	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	2500000	USD
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	7100000	USD
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	7200000	USD
CY2021Q3	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	2300000	USD
CY2020Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	900000	USD
CY2021Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5998000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2358000	USD
CY2021Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	4323000	USD
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	5718000	USD
CY2021Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	1861000	USD
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	3065000	USD
CY2021Q3	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	494000	USD
CY2020Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	542000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	12676000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	11683000	USD
CY2021Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	100000	USD
CY2021Q2	cdcx	Operating Lease Liability Fair Value Of Increase Decrease Due To Lease Modification OperatingLeaseLiabilityFairValueOfIncreaseDecreaseDueToLeaseModification	2200000	USD
CY2021Q2	cdcx	Operating Lease Right Of Use Asset Fair Value Of Increase Decrease Due To Lease Modification OperatingLeaseRightOfUseAssetFairValueOfIncreaseDecreaseDueToLeaseModification	2200000	USD
CY2021Q2	cdcx	Lessee Operating Lease Number Of Renewal Options LesseeOperatingLeaseNumberOfRenewalOptions	1	renewal_option
CY2021Q2	us-gaap	Lessor Operating Lease Renewal Term LessorOperatingLeaseRenewalTerm	P5Y
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3000000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	3300000	USD
CY2020Q3	us-gaap	Lease Cost LeaseCost	188000	USD
	us-gaap	Lease Cost LeaseCost	791000	USD
CY2021Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	152000	USD
CY2020Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	120000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	458000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	359000	USD
CY2021Q3	us-gaap	Variable Lease Cost VariableLeaseCost	51000	USD
CY2020Q3	us-gaap	Variable Lease Cost VariableLeaseCost	5000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	145000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	139000	USD
CY2021Q3	cdcx	Total Operating Lease Expenses TotalOperatingLeaseExpenses	203000	USD
CY2020Q3	cdcx	Total Operating Lease Expenses TotalOperatingLeaseExpenses	125000	USD
	cdcx	Total Operating Lease Expenses TotalOperatingLeaseExpenses	603000	USD
	cdcx	Total Operating Lease Expenses TotalOperatingLeaseExpenses	498000	USD
CY2021Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	63000	USD
CY2020Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	63000	USD
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	188000	USD
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	191000	USD
CY2021Q3	us-gaap	Lease Cost LeaseCost	266000	USD
	us-gaap	Lease Cost LeaseCost	689000	USD
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y9M18D
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.064
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	110000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	669000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	817000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	836000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	808000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	564000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	144000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3948000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	625000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	3323000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	447000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2876000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M18D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.744
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.010
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021Q3	us-gaap	Share Price SharePrice	6.27
CY2021Q3	us-gaap	Share Price SharePrice	6.27
CY2020Q4	cdcx	Unvested Shares Beginning Balance UnvestedSharesBeginningBalance	0	shares
CY2020Q4	cdcx	Unvested Weighted Average Fair Value Beginning Balance UnvestedWeightedAverageFairValueBeginningBalance	0
	cdcx	Unvested Shares Granted UnvestedSharesGranted	123000	shares
	cdcx	Unvested Weighted Average Fair Value Granted UnvestedWeightedAverageFairValueGranted	10.94
	cdcx	Unvested Shares Vested UnvestedSharesVested	0	shares
	cdcx	Unvested Weighted Average Fair Value Vested UnvestedWeightedAverageFairValueVested	0
	cdcx	Unvested Shares Forfeited UnvestedSharesForfeited	7000	shares
	cdcx	Unvested Weighted Average Fair Value Forfeited UnvestedWeightedAverageFairValueForfeited	11.83
CY2021Q3	cdcx	Unvested Shares Ending Balance UnvestedSharesEndingBalance	116000	shares
CY2021Q3	cdcx	Unvested Weighted Average Fair Value Ending Balance UnvestedWeightedAverageFairValueEndingBalance	10.90
	cdcx	Unvested Shares Expected To Vest UnvestedSharesExpectedToVest	116000	shares
	cdcx	Unvested Weighted Average Fair Value Expected To Vest UnvestedWeightedAverageFairValueExpectedToVest	10.90
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	1822000	USD
CY2020Q3	us-gaap	Share Based Compensation ShareBasedCompensation	1574000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4722000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5158000	USD
CY2021Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	10700000	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	reportable_segment
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	reportable_segment
CY2021Q3	us-gaap	Revenues Revenues	17308000	USD
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	6730000	USD
CY2021Q3	us-gaap	Gross Profit GrossProfit	10578000	USD
CY2021Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	7221000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	996000	USD
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11202000	USD
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	19419000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8841000	USD
CY2020Q3	us-gaap	Revenues Revenues	14180000	USD
CY2020Q3	us-gaap	Cost Of Revenue CostOfRevenue	5726000	USD
CY2020Q3	us-gaap	Gross Profit GrossProfit	8454000	USD
CY2020Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5223000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	841000	USD
	us-gaap	Operating Expenses OperatingExpenses	39626000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13773000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6586000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	12650000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4196000	USD
	us-gaap	Revenues Revenues	49690000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	19068000	USD
	us-gaap	Gross Profit GrossProfit	30622000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	19711000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2787000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	29881000	USD
	us-gaap	Operating Expenses OperatingExpenses	52379000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21757000	USD
	us-gaap	Revenues Revenues	43812000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	17959000	USD
	us-gaap	Gross Profit GrossProfit	25853000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	14629000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2545000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22452000	USD
CY2021Q3	us-gaap	Revenues Revenues	17308000	USD
CY2020Q3	us-gaap	Revenues Revenues	14180000	USD
	us-gaap	Revenues Revenues	49690000	USD
	us-gaap	Revenues Revenues	43812000	USD
CY2019Q3	us-gaap	Accounts Receivable From Securitization AccountsReceivableFromSecuritization	1600000	USD

Files In Submission

Name	View Source	Status
0001628280-21-021447-index-headers.html	Edgar Link	pending
0001628280-21-021447-index.html	Edgar Link	pending
0001628280-21-021447.txt	Edgar Link	pending
0001628280-21-021447-xbrl.zip	Edgar Link	pending
cdcx-20210930.htm	Edgar Link	pending
cdcx-20210930.xsd	Edgar Link	pending
cdcx-20210930_cal.xml	Edgar Link	unprocessable
cdcx-20210930_def.xml	Edgar Link	unprocessable
cdcx-20210930_g1.jpg	Edgar Link	pending
cdcx-20210930_htm.xml	Edgar Link	completed
cdcx-20210930_lab.xml	Edgar Link	unprocessable
cdcx-20210930_pre.xml	Edgar Link	unprocessable
cdxcq3202110qex-311.htm	Edgar Link	pending
cdxcq3202110qex-312.htm	Edgar Link	pending
cdxcq3202110qex-321.htm	Edgar Link	pending
exclusivelicenseagreementd.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
seventhamendmenttomanufact.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CDXC
ChromaDex Corp. Stock $cdxc

2021 Q4 Form 10-Q Financial Statement

#000162828021021447 Filed on November 03, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDXC ChromaDex Corp. Stock $cdxc

2021 Q4 Form 10-Q Financial Statement

#000162828021021447 Filed on November 03, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDXC
ChromaDex Corp. Stock $cdxc